Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.
   Google Scholar   
Citation:
J Gastrointest Cancer vol 38 (1) 10-4
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
CA25224, CA37404, CA60276  
Corr. Author:
 
Authors:
           
Primary Study
NCCTG-964251
Secondary Studies:
Phases:
2
Keywords:
Adult, Aged, Antineoplastic Agents, Carcinoma, Hepatocellular, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Pyrrolidinones, Treatment Outcome